🚀 VC round data is live in beta, check it out!
Zhejiang Ausun Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zhejiang Ausun and similar public comparables like Concord Biotech, Guilin Sanjin, Pharming, EyePoint and more.
Zhejiang Ausun Overview
About Zhejiang Ausun
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
Founded
2010
HQ
Employees
N/A
Website
Financials (FY)
EV
$1B
Zhejiang Ausun Financials
Zhejiang Ausun reported last fiscal year revenue of $117M and EBITDA of $46M.
In the same fiscal year, Zhejiang Ausun generated $63M in gross profit, $46M in EBITDA, and $30M in net income.
Revenue (LTM)
Zhejiang Ausun P&L
In the most recent fiscal year, Zhejiang Ausun reported revenue of $117M and EBITDA of $46M.
Zhejiang Ausun expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $117M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $63M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 54% | XXX | XXX | XXX |
| EBITDA | — | XXX | $46M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 39% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 26% | XXX | XXX | XXX |
| Net Profit | — | XXX | $30M | XXX | XXX | XXX |
| Net Margin | — | XXX | 26% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zhejiang Ausun Stock Performance
Zhejiang Ausun has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Zhejiang Ausun's stock price is $1.48.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.0% | XXX | XXX | XXX | $0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZhejiang Ausun Valuation Multiples
Zhejiang Ausun trades at 9.6x EV/Revenue multiple, and 24.4x EV/EBITDA.
EV / Revenue (LTM)
Zhejiang Ausun Financial Valuation Multiples
As of April 20, 2026, Zhejiang Ausun has market cap of $1B and EV of $1B.
Equity research analysts estimate Zhejiang Ausun's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zhejiang Ausun has a P/E ratio of 40.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 24.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 36.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 17.6x | XXX | XXX | XXX |
| P/E | — | XXX | 40.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 114.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zhejiang Ausun Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zhejiang Ausun Margins & Growth Rates
Zhejiang Ausun's revenue in the last fiscal year declined by (3%).
Zhejiang Ausun Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (3%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 39% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (8%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zhejiang Ausun Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zhejiang Ausun | XXX | XXX | XXX | XXX | XXX | XXX |
| Concord Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Guilin Sanjin | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| EyePoint | XXX | XXX | XXX | XXX | XXX | XXX |
| Idorsia | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhejiang Ausun M&A Activity
Zhejiang Ausun acquired XXX companies to date.
Last acquisition by Zhejiang Ausun was on XXXXXXXX, XXXXX. Zhejiang Ausun acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zhejiang Ausun
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZhejiang Ausun Investment Activity
Zhejiang Ausun invested in XXX companies to date.
Zhejiang Ausun made its latest investment on XXXXXXXX, XXXXX. Zhejiang Ausun invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zhejiang Ausun
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zhejiang Ausun
| When was Zhejiang Ausun founded? | Zhejiang Ausun was founded in 2010. |
| Where is Zhejiang Ausun headquartered? | Zhejiang Ausun is headquartered in China. |
| Is Zhejiang Ausun publicly listed? | Yes, Zhejiang Ausun is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Zhejiang Ausun? | Zhejiang Ausun trades under 603229 ticker. |
| When did Zhejiang Ausun go public? | Zhejiang Ausun went public in 2017. |
| Who are competitors of Zhejiang Ausun? | Zhejiang Ausun main competitors are Concord Biotech, Guilin Sanjin, Pharming, EyePoint. |
| What is the current market cap of Zhejiang Ausun? | Zhejiang Ausun's current market cap is $1B. |
| What is the current revenue of Zhejiang Ausun? | Zhejiang Ausun's last fiscal year revenue is $117M. |
| What is the current EV/Revenue multiple of Zhejiang Ausun? | Current revenue multiple of Zhejiang Ausun is 9.6x. |
| Is Zhejiang Ausun profitable? | No, Zhejiang Ausun is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.